Clinical trial · Interventional
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
NCT02755675CI-TRIAL-00024848unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
uPAR PET/CT as a prognostic marker in non-small cell lung cancer.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Large Cell Neuroendocrine Carcinoma of the Lung | Lung Large Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
| Malignant Pleural Mesothelioma | Pleural Malignant Mesothelioma | ALIAS | 0.90 |
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 68Ga-NOTA-AE105 PET/CT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 68Ga-NOTA-AE105 PET/CT
- description
- One injection of 68Ga-NOTA-AE105 followed by positron emission tomography/computed tomography (PET/CT scan) will be performed before treatment start to evaluate the prognostic value of uPAR PET/CT.
- interventionNames
- Other: 68Ga-NOTA-AE105 PET/CT
Primary outcomes (3)
- measure
- Study Ia: Overall survival (OS)
- timeFrame
- Study Ia: OS is evaluated after clinical follow-up for 18 months (stage IV disease)
- measure
- Study Ib: Overall survival (OS)
- timeFrame
- Study Ib: OS is evaluated after clinical follow-up for 60 months (operable disease)
- measure
- Study II and III: Uptake of 68Ga-NOTA-AE105 in primary tumor lesion (dichotomized +/-)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: Study I * Histologically verified NSCLC (Study I) * Stage IV disease * Operable disease * The participants must be capable of understanding and giving full informed written consent Study II * Histologically verified MPM (Study II) * The participants must be capable of understanding and giving full informed written consent Study III * Histologically verified LCNEC (Study III) * The participants must be capable of understanding and giving full informed written consent Exclusion Criteria: Study I, II, III * Pregnancy * Lactation/breast feeding * Treatment with neoadjuvant chemotherapy * Weight above 140 kg * Allergy to 68Ga-NOTA-AE105
References
Publications (0)
Data not yet available
No reference posted for this study.